- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02607787
EXercise And Colo-Rectal Cancer Trial (EXACT)
The Feasibility and Effects of a Home-based Walking and Strengthening Intervention on Physiological, Biochemical and Psychological Outcomes in Colo-rectal Cancer Survivors
The aim of this study is to assess the feasibility and effectiveness of a home-based walking and strengthening intervention on physiological, biochemical and psychological outcomes in colo-rectal cancer survivors.
The intervention consists of a 12-week home-based walking and strengthening programme for colo-rectal cancer survivors post any anti-cancer treatment. It aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
As well as usual care, the intervention group will receive weekly telephone calls and a behaviour change interview at baseline. Participants will be recruited from the Cancer Centre at the Belfast City Hospital. Assessments will be taken at baseline (0 weeks), post intervention (12 weeks) and also at a 3-month follow-up (24 weeks). The control group will receive the same assessments at the same time-points however they will continue to receive usual care with the intervention information (including pedometer, exercise booklet, diary and behavioural change interview) being given at the 3-month follow-up appointment.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The number of people living with and beyond cancer is ever increasing and now more than ever there is a need to facilitate the appropriate rehabilitation of these patients. Exercise interventions and increased physical activity have been well documented in their ability to improve multiple aspects of health in cancer survivors; including quality of life, fatigue as well as all-cause and cancer-specific mortality. Whilst the main outcome from this study will be its feasibility, the novel aspect is the analysis of biological markers in the blood. Although there is much evidence on the benefits of exercise for colo-rectal cancer survivors, the biological mechanisms underlying its effects in this population are still elusive. Therefore this intervention was designed to investigate the feasibility and effectiveness of a home-based walking and strengthening programme on physiological, biochemical and psychological outcomes in colo-rectal cancer survivors.
Participants are first approached by their surgeon/oncologist and assessed for their eligibility. If they are deemed eligible they are then referred to the researcher in the waiting room to be given more information about the study. If interested, they receive the participant information sheet and consent forms to take home for a period of at least 24 hours, after which the researcher calls to confirm their interest. Visit 1 is then scheduled in order for the participant to sign the consent forms and receive the 'ActiGraph' accelerometer which they wear for 7 consecutive days in order to measure their baseline physical activity levels. With permission, the patients GP will be advised by letter that the patient is commencing the study.
After the seven days the participant attends the Northern Ireland Clinical Research Facility at the Belfast City Hospital for the first assessment session. The outcome measures assessed include analysis on feasibility, quality of life, fatigue, biological markers, anthropometry, strength, cardiovascular endurance and physical activity levels. The intervention group then receive the behaviour change counselling session along with the exercise booklet, diary and pedometer. Weekly phone calls are made to intervention participants for 12 weeks to monitor their progress. The control group receives usual care without weekly phone calls. On week 11 both groups are posted their accelerometer to record activity levels and then attend the City Hospital to repeat all assessments. Both groups are not contacted again until week 23 when they are posted the accelerometer for the final time and their follow-up assessments are complete. It is at this assessment session that the control group receive the behaviour change session and intervention materials.
After each assessment day, blood samples are transported via a specifically designed fridge, to the Ulster University campus to be stored at -80 degrees Celsius for future analysis. All other study information such as questionnaires and collected data are stored as per University protocol in storage containers in a designated locked room on campus.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Antrim
-
Belfast, Antrim, Zjednoczone Królestwo, BT9 7AB
- Rekrutacyjny
- Belfast City Hospital
-
Kontakt:
- Jane Rankin, MSc
- Numer telefonu: 028 9069 9369
- E-mail: jane.rankin1@belfasttrust.hscni.net
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Dukes A-C colo-rectal cancer patients at least 6 weeks post any-type anti-cancer treatment, as identified by the colo-rectal oncologic and surgical teams at the Cancer Centre, Belfast City Hospital, Belfast Health and Social Care Trust.
- Males and females.
- Over eighteen years of age.
- Physically able to undertake the intervention as described within the HBWS programme by Donnelly and colleagues (2010).
- Ambulatory and without use of a walking aid.
Exclusion Criteria:
- Still undergoing and/or scheduled for further anti-cancer treatment.
- Any presence of cognitive impairment.
- Known co-morbidities which would severely impact upon physical functioning or nutritional status such as poorly controlled diabetes, heart failure, unstable angina, degenerative neuromuscular disease, inborn errors of metabolism, mental health disorder or substance abuse.
- Already meeting the current recommended physical activity guidelines (Schmitz, et al. 2010).
- Unable to understand and communicate in written and oral English and over the phone sufficiently well enough to undertake the self-management programme and weekly telephone review.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Exercise Group
As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme.
The home-based walking and strengthening intervention is individually tailored for each participant.
They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
|
The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
|
|
Inny: Control Group
This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study.
However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24.
They are aware of their group allocation throughout the duration of the study.
|
The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested.
They will however receive the intervention information on their last visit.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Feasibility
Ramy czasowe: 24 months
|
The feasibility of the trial will be characterized by recording such things as; the number of eligible patients, the follow-up rates, response rates to questionnaires and adherence/compliance rates.
|
24 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Physical activity
Ramy czasowe: For 7 days at three different times; baseline, week 11 and week 23.
|
The participants will wear an 'ActiGraph' accelerometer around their waist for 7 consecutive days in order to calculate their activity levels.This will be measured by analyzing the minutes spent in moderate/vigorous/sedentary behaviour.
|
For 7 days at three different times; baseline, week 11 and week 23.
|
|
Cardiovascular Endurance
Ramy czasowe: Week 0, 12 and 24
|
Participants walk between two cones 30 metres apart for six minutes.
The cones are in a closed off corridor in the hospital with no obstructions.
This is measured in meters covered in the 6 minutes.
|
Week 0, 12 and 24
|
|
Lower limb strength
Ramy czasowe: Week 0, 12 and 24
|
The 30 second sit-to-stand test requires the participants to sit down and stand up from a chair as many times as they can in 30 seconds.
The outcome is the number of repetitions completed.
|
Week 0, 12 and 24
|
|
Quality of life
Ramy czasowe: Week 0, 12 and 24
|
Various validated questionnaires will be given to assess quality of life and fatigue; Positive and Negative Affect Schedule (PANAS), EQ-5D-3L questionnaire, FACT-C and FACT-F.
|
Week 0, 12 and 24
|
|
Demographics
Ramy czasowe: Week 0, 12 and 24
|
A specially designed demographics questionnaire to gain an insight into the participant characteristics.
Outcomes measured will be; age/ethnicity/employment status/marital status.
|
Week 0, 12 and 24
|
|
Height
Ramy czasowe: Week 0, 12 and 24
|
Height will be measured in metres/cm.
|
Week 0, 12 and 24
|
|
Venous blood sample
Ramy czasowe: Week 0, 12 and 24
|
A 34ml venous blood sample will be taken to measure various markers.
|
Week 0, 12 and 24
|
|
Weight
Ramy czasowe: Week 0, 12 and 24
|
Weight will be measured in kg.
|
Week 0, 12 and 24
|
|
Hip and waist circumference
Ramy czasowe: Week 0, 12 and 24
|
Measured using a measuring tape in cm.
|
Week 0, 12 and 24
|
|
Capillary blood sample
Ramy czasowe: Week 0, 12 and 24
|
Finger prick test performed to measure metabolism related markers.
|
Week 0, 12 and 24
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Jackie Gracey, PhD, Ulster University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 14/0061 (EXACT Study)
- 14127JG-SS (Inny identyfikator: HSC Trust UK)
- 14/NI/1048 (Inny identyfikator: ORECNI)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak jelita grubego
-
University of ChicagoJeszcze nie rekrutacjaHER2 Pozytywne nowo zdiagnozowane przerzuty przełyku, żołądka, GEJ Cancer Pacjenci ze statusem wydajności ECOG 2
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)Jeszcze nie rekrutacjaSyndrom Lyncha | Dziedziczny zespół nowotworowy | BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome | BRCA2-Related Hereditary Breast and Ovarian Cancer SyndromeStany Zjednoczone
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.Aktywny, nie rekrutującyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)ZakończonyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)ZakończonyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Korea Południowa
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
Badania kliniczne na Exercise
-
Rashid Latif Medical CollegeZakończonyZespół wielotorbielowatych jajnikówPakistan
-
Riphah International UniversityZakończonyFizjoterapia sportowaPakistan
-
Istanbul University - CerrahpasaRekrutacyjnyMotoryczny zespół ryzyka poznawczego | Osoby w podeszłym wieku (osoby w wieku 65 lat lub starsze) | Pacjent geriatryczny | Eksergowanie | Ćwiczenia nerwowo-mięśnioweTurcja (Türkiye)
-
Cukurova UniversityZakończonyZespół nadpobudliwości psychoruchowej z deficytem uwagi (ADHD)Turcja (Türkiye)
-
Sanidad de Castilla y LeónZakończonySkuteczność programu poprawiającego równowagę, mobilność i zapobiegającego upadkom u osób starszych.Przypadkowe upadkiHiszpania
-
INTI International UniversityUniversiti Pendidikan Sultan IdrisZakończony
-
The Hong Kong Polytechnic UniversityZakończonyBezsenność, podstawowyHongkong
-
Technical University of MunichZakończonyPobór energii | Zdrowie | Apetyt | Zachowania żywienioweNiemcy
-
Université Catholique de LouvainKU Leuven; Epsylon, ASBLJeszcze nie rekrutacja
-
Hacettepe UniversityRekrutacyjnyBóle krzyża | Skolioza idiopatyczna | PowięźTurcja (Türkiye)